ResearchClaude

Anthropic launches Claude Science for drug development

Original title: Early progress on accelerating drug development with Claude

Plain language

What it is: Anthropic announced progress in using Claude to speed up drug development through partnerships with six healthcare organizations and its own research projects. The company also launched Claude Science, an AI workbench for researchers, and a program to provide credits for scientists.
How it works: Claude helps with tasks across the entire drug development process, such as designing molecules, analyzing lab data, drafting regulatory paperwork, and organizing logistics. It can automate administrative tasks and analyze large volumes of scientific documents to find errors.
Where it is available: These tools and programs are available for life science researchers and biotechnology organizations, specifically through Claude Science and the Life Sciences Verification Program.
Example: Enveda used Claude to review manufacturing documents, and the model found all 11 errors previously identified by humans plus 7 errors that humans had missed.

What it is: Anthropic is partnering with life science organizations and running internal programs to apply Claude to drug discovery, while launching Claude Science and the Life Sciences Verification Program.
How it works: Researchers use Claude and Claude Code to generate antibody designs, propose molecular modifications by integrating with lab data systems, and draft regulatory filings. The models analyze raw experimental data, suggest new testing metrics, and automate document verification.
Where it is available: The capabilities are applied in preclinical research and early clinical trials, accessible via Claude Science, Claude Code, and the Life Sciences Verification Program.
Example: Generate Biomedicines used Claude Code to design shorter genetic instructions for CAR T-cell therapy, creating a design that was 70% shorter and more effective in laboratory tests.

The headline and explanation on this page are based on Anthropic's post. The full details are in the original.

Early progress on accelerating drug development with Claude